Emerging antibody-drug conjugates for treating lymphoid malignancies
Anna Wolska-Washer1, Pawel Robak2, Piotr Smolewski2
1a Department of Hematology , Medical University of Lodz , Lodz , Poland.
Expert Opinion on Emerging Drugs
|August 10, 2017
Summary
Antibody-drug conjugates (ADCs) show promise for treating blood cancers like lymphoma and leukemia by targeting cancer cells. Further clinical trials are needed to confirm their effectiveness and optimal use.
Area of Science:
- Oncology
- Hematology
- Pharmacology
Background:
- Antibody-drug conjugates (ADCs) combine monoclonal antibodies (Mabs) with cytotoxic drugs via linkers.
- ADCs aim to enhance chemotherapy potency by concentrating cytotoxic agents at tumor sites.
- This targeted delivery reduces systemic exposure and associated toxicities.
Purpose of the Study:
- To review the literature on Mabs, B-cell receptor pathway inhibitors, and immunomodulating drugs.
- To assess the current and emerging role of ADCs in hematologic malignancies.
Main Methods:
- Literature search of MEDLINE (PubMed) for English articles from 2000-2017.
- Manual search of conference proceedings from major hematology and oncology societies.
- Reference review of selected publications.
Main Results:
- ADCs are emerging as promising treatments for hematologic malignancies.
- Specific hematologic cancers showing potential include lymphoma, multiple myeloma, and leukemia.
Conclusions:
- Newer ADCs demonstrate potential in treating various hematologic malignancies.
- Definitive data from ongoing and future clinical trials are crucial for establishing the role of ADCs.
Keywords:
A-dmDT390-bisFvADCT-301AGS67EAnti-FcrL5DCDT2980SDCDTS4501ALMB-2SAR-3419antibody-drug conjugatebrentuximab vedotincombotoxdenileukin diftitoxdenintuzumab mafodotinindatuximab ravtansineinotuzumab ozogamicinleukemialorvotuzumab mertansinelymphomamilotuzumab-doxmoxetumomab pasudotoxmultiple myelomapinatuzumab vedotinpolatuzumab vedotinresimmuneMore Related Videos
Related Concept Videos
Hybridoma Technology
18.0K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
18.0K
Antibody Actions
3.1K
Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
3.1K
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K


